Breaking the Efflux Barrier: P-Glycoprotein and Emerging Strategies to Overcome Multidrug Resistance in Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multidrug resistance (MDR) is a significant challenge in cancer therapy.
• Overexpression of ATP-binding cassette (ABC) transporters, like P-glycoprotein (P-gp/ABCB1), is a primary cause of MDR.
• P-gp actively removes chemotherapy drugs from cancer cells, reducing treatment efficacy.

Purpose of the Study:

• To comprehensively review the molecular mechanisms of P-gp function in MDR.
• To analyze the interplay of P-gp with oxidative stress, metabolic reprogramming, and the tumor microenvironment.
• To discuss emerging therapeutic strategies for overcoming P-gp-mediated resistance.

Main Methods:

• Literature review and analysis of existing research on P-gp and MDR.
• Examination of P-gp structure, expression regulation, and drug efflux mechanisms.
• Synthesis of information on novel therapeutic approaches targeting P-gp.

Main Results:

• P-gp's role in reducing intracellular drug accumulation and promoting treatment failure is detailed.
• The complex, dynamic nature of MDR involving P-gp, cellular stress, and the tumor microenvironment is highlighted.
• Various emerging strategies, including natural compounds and nanodelivery systems, show promise in overcoming P-gp resistance.

Conclusions:

• Understanding P-gp's intricate mechanisms is crucial for developing effective cancer therapies.
• Integrating mechanistic insights with novel pharmacological strategies can enhance intracellular drug retention.
• Targeting P-gp-mediated resistance is essential for improving clinical outcomes in cancer patients.